References
- Gaspari AA. Mechanism of action and other potential roles of an immune response modifier. Cutis. 2007; 79((4 suppl))36–45
- Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol. 1998; 134: 25–30
- Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004; 50: 722–33
- Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, et al. Imiquimod 5% cream for the treatment of actinic keratosis: Results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004; 50: 714–21
- Jorizzo J, Dinehart S, Matheson R, Moore JK, Ling M, Fox TL, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol. 2007; 57: 265–8
- Wagstaff AJ, Perry CM. Topical imiquimod: A review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs. 2007; 67: 2187–210
- Food and Drug Administration Center for Drug Evaluation and Research; Approved drug products with therapeutic equivalence evaluations, 28th ed. Accessed 3 September 2008. URL:. http://www.fda.gov/cder/ob/docs/preface/ecpreface.htm
- European Agency for the Evaluation of Medicinal Products. Note for guidance on the investigation of bioavailability and bioequivalence. Report no.: CPMP/EWP/QWP/1401/98. London: EMEA; 2002. p. 14–15.
- Flynn GL, Shah VP, Tenjarla SN, Corbo M, DeMagistris D, Feldman TG, et al. Assessment of value and applications of in vitro testing of topical dermatological drug products. Pharm Res. 1999; 16: 1325–30
- Us Food and Drug Administration. Nonsterile semisolid dosage forms. Scale-up and postapproval changes: chemistry, manufacturing and controls; in vitro release testing and in vivo bioequivalence. SUPAC-SS CMC 7. FDA: Rockville, MD; 1997.
- Office of Generic Drugs, Office of Pharmaceutical Science, Center for Drug Evaluation and Research. Critical path opportunities for generic drugs. 1 May 2007. Accessed 3 September 2008. URL:. http://www.fda.gov/oc/initiatives/criticalpath/reports/generic.html#dermatological
- Federal Register: 17 May 2002 (Volume 67, Number 96), p. 35 122–3.
- Chollet JL, Jozwiakowski MJ, Phares KR, Reiter MJ, Roddy PJ, Schultz HJ, et al. Development of a topically active imiquimod formulation. Pharm Dev Technol. 1999; 4: 35–43
- Chollet JL, Lippert DR, Myrdal PB, Jozwiakowski MJ, Pachuta RR, Li ZJ. Crystal formation by drug-excipient interaction in a topical imiquimod formulation. AAPS Annual Meeting, 1998: Abstract 2445. URL:. http://www.aapsj.org/abstracts/AM_1998/2445.html
- Sequira J, Berardi M, Chan TM, Letarte J, Malchow R, Pramanick B, et al. Assessing equivalence of innovator and generic formulations of betamethasone dipropionate cream and ointment. Clin Ther. 1991; 13: 687–94
- Stoughton RB. Are generic formulations equivalent to trade name topical glucocorticoids?. Arch Dermatol. 1987; 123: 1312–14
- Hadgraft J, Whitefield M, Rosher PH. Skin penetration of topical formulations of ibuprofen 5%; an in vitro comparative study. Skin Pharmacol Appl Skin Physiol. 2003; 16: 137–42
- Trottet L, Owen H, Holme P, Heylings J, Collin IP, Breen AP, et al. Are all acyclovir cream formulations bioequivalent?. Int J Pharm. 2005; 304((1–2))63–71
- Gao HY, Li Wan Po A. Topical formulations of fluocinolone acetonide. Are creams, gels and ointments bioequivalent and does dilution affect activity? Eur J Clin Pharmacol. 1994; 46: 71–5